Anavex Life Sciences Corp (AVXL)

[XenaLives]

Reprinted from over a year ago..

My point is that there is no "normal" process in the EU at this time. Where did you get your 2% figure? The fact is that if 2-73 is a significant improvement over L-dopa for Parkinson's it will go through the regulatory process in an expedited manner.

Dr. Angela Cenci-Nilsson was Dr. Veronica Francardo's PHD sponsor.
Quote:

"L-dopa…waiting for the next act" with Dr. Angela Cenci-Nilsson
Published on Published onFebruary 8, 2016
Elizabeth (Eli) Pollard

Executive Director at World Parkinson Coalition
19 articles

Why has it taken over 50 years to improve the delivery systems of L-dopa and what can people with Parkinson's expect in the near future? Dr. Angela Cenci-Nilsson of Lund University and who sits on the WPC 2016 Steering Committee, is this month's special guest on the Portland Countdown podcast program. She talks about "L-dopa … waiting for the next act" with Jon Palfreman and Dave Iverson.
I often hear people talk about how ridiculous it is that l-dopa is still the golden drug of choice for addressing Parkinson's symptoms. People want more treatment options, but those who use l-dopa and get good results, could't live without this "old" drug. Isn't it possible to have researchers keep fine tuning the drugs on the market, while others keep searching for new treatments? Dave says in the podcast that refining drugs is not sexy or that lucrative for pharma, but he and Jon agree that refining some of these old drugs, like levodopa is crucial to improving the lives of PwP.
Should people with Parkinson's become more involved in the research process and move from advocates to activists in order to influence funding decisions? PD activists might have more success influencing researchers and companies to do some of the research they may not be that eager to take on, such as the refining of drugs already on the market.
I often hear that PwP are too nice, and that if they want to get more done, they need to take a page out of the AIDS activists' book and get more aggressive in order to push for more changes in treatment options or to refine the drugs that are already on the market.
Is now the time to get more aggressive? If you could dictate PD research right now, starting immediately, what would you ask researchers to focus on?

https://www.linkedin.com/pulse/l-dopawaiting-next-act-dr-angela-cenci-nilsson-pollard/

Original post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137969688